Octapharma

Octapharma is a privately held Swiss biopharmaceutical company founded in 1983 by Wolfgang Marguerre. The company develops and manufactures therapies based on human proteins obtained from donated plasma or produced through recombinant technologies using human cell lines. Its work is concentrated in three principal therapeutic areas: hematology, immunotherapy, and critical care. The company originated with a focus on coagulation medicine. Its name refers to factor VIII, the blood-clotting protein whose deficiency causes hemophilia A. Octapharma's first product was a factor VIII concentrate made using solvent-detergent virus-inactivation technology, which was an important safety approach for plasma-derived medicines at the time. The company subsequently broadened its portfolio to include therapies for hemophilia A and B, von Willebrand disease, primary and secondary immune deficiencies, autoimmune and neurological disorders, and acute-care settings. In hematology, Octapharma supplies high-purity coagulation-factor products for people with inherited or acquired bleeding disorders. In immunotherapy, its medicines are used either to replace deficient antibodies or to modulate immune responses in immune-mediated disease. Its critical-care activities address situations in which plasma proteins may be required during intensive care, emergency medicine, major surgery, trauma, burns, or other severe conditions. The company also identifies applications involving cancer care and protection of newborns in pregnancies involving Rh incompatibility. Octapharma's manufacturing model begins with the collection and qualification of source plasma. Plasma is fractionated into constituent proteins and then subjected to purification, virus-inactivation, quality testing, and release controls. The company also uses recombinant production methods based on human cell lines, allowing some proteins to be produced without relying exclusively on plasma donations. Its activities therefore span plasma collection, research and development, industrial production, regulatory operations, and global distribution. Octapharma operates internationally, with products used in approximately 120 countries. Reference material for the end of 2024 describes a workforce of about 11,000 people, seven research and development sites, five manufacturing facilities in Austria, France, Germany, and Sweden, and more than 190 plasma-donation centers in Europe and the United States. The US plasma-collection business operates under the Octapharma Plasma name. The company remains family-owned by the Marguerre family. Wolfgang Marguerre is identified as chairman and chief executive, while Tobias Marguerre has served as deputy chairman. Family ownership and long-term control distinguish Octapharma from publicly traded pharmaceutical groups, although the company operates at multinational scale and serves highly regulated markets. Octapharma's history also includes a significant cybersecurity event. In April 2024, Octapharma Plasma temporarily stopped operations at its US plasma-donation centers after detecting unauthorized network activity consistent with a cyberattack. Subsequent reporting indicated that a threat actor associated with BlackSuit ransomware accessed the network and exfiltrated files containing personal information. The company notified the Federal Bureau of Investigation and the California attorney general. This incident affected the operational and data-security dimensions of a business whose supply chain depends on a distributed network of donation centers.

Octapharma was established in 1983 by Wolfgang Marguerre, a German businessman with prior experience in the pharmaceutical sector. The company was created around the development of medicines based on human proteins, either isolated from human plasma or made through recombinant biological techniques. Its name alludes to factor VIII, a coagulation protein that is deficient in people with hemophilia A. The company's first product was a factor VIII concentrate manufactured with solvent-detergent virus-inactivation technology. This technology was significant because viral safety is a central concern for products made from human plasma. From this initial hematology focus, Octapharma developed a broader platform covering plasma collection, protein fractionation, purification, virus inactivation, quality inspection, recombinant production, and distribution of specialized medicines. Octapharma's therapeutic scope expanded into three principal areas. Hematology addresses inherited and acquired bleeding disorders, including hemophilia A, hemophilia B, and von Willebrand disease. Immunotherapy covers immunoglobulin replacement for antibody deficiencies and immune modulation for autoimmune, neurological, and other immune-mediated disorders. Critical care applies plasma-derived and other protein products to intensive-care and emergency situations, including severe injury, burns, major surgery, and other acute conditions. The business model has both manufacturing and collection components. Source plasma is collected, qualified, fractionated, and processed into therapeutic proteins. Each resulting therapy passes through purification, virus-inactivation, testing, and inspection steps before release. In parallel, Octapharma uses recombinant methods involving human cell lines for selected protein products. This combination gives the company capabilities in both plasma-derived and cell-line-based biologics. Octapharma remains privately owned by the Marguerre family. Wolfgang Marguerre has been identified as chairman and chief executive, and Tobias Marguerre as deputy chairman. Frederic Marguerre has also served on the management board. The family structure has allowed the company to remain outside public equity markets while building a multinational operating network. By the end of 2024, reference material described Octapharma as employing roughly 11,000 people and supplying products used in approximately 120 countries. Its infrastructure included seven research and development sites, five manufacturing facilities located in Austria, France, Germany, and Sweden, and more than 190 plasma-donation centers across Europe and the United States. The US collection operation is branded Octapharma Plasma. A major recent event occurred in April 2024, when Octapharma Plasma temporarily suspended operations at its US donation centers after detecting unauthorized network activity. Publicly described information connected the event with a cyberattack and reported that a threat actor identified in coverage as BlackSuit ransomware accessed the network and removed files containing personal information. Octapharma notified the Federal Bureau of Investigation and the California attorney general. The incident highlighted the cybersecurity exposure created by a geographically distributed plasma-collection business and the sensitivity of donor and operational data.

• 2024

  US plasma centers temporarily shut after cyber incident

  [1]Octapharmaen.wikipedia.org

  Octapharma Plasma pauses activity at its US plasma-donation centers after detecting unauthorized network activity and later reports data exfiltration to authorities.

• 2024

  Global network reported at expanded scale

  [1]Octapharmaen.wikipedia.org

  Reference information for year-end 2024 describes approximately 11,000 employees, seven R&D sites, five manufacturing facilities, and more than 190 plasma centers.

• 1983

  Octapharma is founded

  [1]Octapharmaen.wikipedia.org

  Wolfgang Marguerre establishes Octapharma as a pharmaceutical company focused on human-protein therapies.

• 1983

  First factor VIII concentrate introduced

  [1]Octapharmaen.wikipedia.org

  The company's inaugural product is a factor VIII concentrate produced using solvent-detergent virus-inactivation technology.

A privately owned international specialist in human-protein medicines, combining plasma fractionation, recombinant biotechnology, and a vertically integrated plasma-collection and manufacturing network.

• Hematology · 1983

  Factor VIII concentrates

  Octapharma began with factor VIII therapy for hemophilia A. Factor VIII concentrates replace or supplement the clotting protein missing or insufficient in affected patients and represent the historical foundation of the company's hematology business. Octapharma has developed both plasma-derived and recombinant approaches within its broader human-protein technology platform.

• Immunotherapy

  Immunoglobulin therapies

  Human immunoglobulin products are used in antibody-replacement therapy for primary and secondary immune deficiencies and in immune modulation for selected autoimmune, neurological, and other immune-mediated disorders. These products are made from human plasma and require extensive fractionation, purification, viral-safety controls, and quality testing.

• Hematology

  Coagulation therapies for hemophilia B and von Willebrand disease

  Octapharma's hematology portfolio extends beyond factor VIII to products intended for other inherited bleeding conditions, including hemophilia B and von Willebrand disease. These therapies are designed to replace deficient coagulation proteins or otherwise support hemostasis in patients at risk of abnormal bleeding.

• Critical care

  Critical-care plasma and protein products

  The company supplies human plasma and protein products for intensive care, emergency medicine, trauma, burns, major surgery, and other acute clinical situations. The products are part of Octapharma's wider plasma-protein platform and are manufactured under controls covering fractionation, purification, viral inactivation, inspection, and release.

• 2024

  Octapharma Plasma cybersecurity and data-exfiltration incident

  In April 2024, Octapharma Plasma temporarily halted operations at its US plasma-donation centers after detecting unauthorized network activity consistent with a cyberattack. Publicly described information associated the incident with BlackSuit ransomware and indicated that files containing personal information were accessed and exfiltrated. The company notified the FBI and the California attorney general.

  Source

Read more

• 2024

  Temporary suspension of US plasma-center operationsOther

  Background

  Octapharma Plasma detected unauthorized network activity consistent with a cyberattack affecting its US donation-center operations.

  Action taken

  The company temporarily halted operations, investigated the incident, and reported it to the FBI and the California attorney general.

  Aftermath

  Publicly described information indicated that a threat actor accessed the network and exfiltrated files containing personal information.

  Source

• 1983

  Launch of the company's first factor VIII productProduct launch

  Background

  Octapharma was founded around the development of human-protein medicines, with hemophilia A and factor VIII as the defining initial focus.

  Action taken

  The company introduced a factor VIII concentrate manufactured using solvent-detergent virus-inactivation technology.

  Aftermath

  The product established the company's initial position in hematology and provided the platform for later expansion into immunotherapy and critical care.

  Source

• 2024

  Octapharma reports expanded global operating scale[1]Octapharmaen.wikipedia.org

  Other

  Reference information for December 31, 2024 describes approximately 11,000 employees, seven research and development sites, five manufacturing facilities, and more than 190 plasma-donation centers serving patients in about 120 countries.

1. 1Octapharmaen.wikipedia.org
2. 2Octapharma official websiteoctapharma.com